Advanced search
Publication Cover
Future Oncology Volume 19, 2023 - Issue 9
Submit an article Journal homepage
2,933
Views
0
CrossRef citations to date
0
Altmetric
Clinical Trial Evaluation

STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2

Amer M Zeidan1 Yale University & Yale Cancer Center, New Haven, CT 06510, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7017-8160View further author information
ORCID Icon,
Aristoteles Giagounidis2 Marien Hospital Düsseldorf, Düsseldorf, 40479, GermanyView further author information
,
Mikkael A Sekeres3 Division of Hematology, Sylvester Cancer Center, University of Miami, Miami, FL 33065, USAView further author information
,
Zhijian Xiao4 Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, 300020, ChinaView further author information
,
Guillermo F Sanz5 Hospital Universitario y Politécnico La Fe, Valencia, 46026, Spain;6 Health Research Institute La Fe (IIS La Fe), Valencia, 46026, Spain;7 CIBERONC, Instituto de Salud Carlos III, Madrid, 28029, SpainView further author information
,
Marlies Van Hoef8 Novartis Pharma AG, Basel, 4056, SwitzerlandView further author information
,
Fei Ma9 Novartis Pharmaceuticals Corporation, East Hanover, NJ07936, USAView further author information
,
Sabine Hertle8 Novartis Pharma AG, Basel, 4056, SwitzerlandView further author information
&
Valeria Santini10 MDS Unit, Hematology, University of Florence, Florence, 50121, ItalyCorrespondence[email protected]
View further author information
 show all
Pages 631-642 | Received 08 Dec 2022, Accepted 06 Mar 2023, Published online: 21 Apr 2023

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.